A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Next Previous
Trial Profile

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs LN 144 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics

    • Most Recent Events

    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, results from cohort 2, were presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, to date, Iovance has 11 active clinical sites in the United States and intends to start enrolling patients at clinical sites in Europe in early 2018. Cohort 1 of the study will be closed and new patients will be enrolled in cohort 2.
    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, updated data of patients in cohort 2 will be presented at Analyst Day 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top